News Roundup: Weatherford International plc (NYSE:WFT), Galena Biopharma, Inc. (NASDAQ:GALE)

177

Weatherford International plc (NYSE:WFT)

The company announced its last quarter financial performance results on 02/02/2017. Weatherford International plc (NYSE:WFT) belongs to Oils-Energy sector that declined -2.28% in value when last trading session closed at $6. The company has a market capitalization of $5.53 Billion. The company’s stock has a Return on Assets (ROA) of 0 percent, a Return on Equity (ROE) of 0 percent and Return on Investment (ROI) of 0 percent. The company reached its 52-Week high of $8.49 on Apr 27, 2016 and 52-Week low of $3.73 on Nov 8, 2016.

Earnings per share (ttm) for Weatherford International plc (NYSE:WFT) according to Finviz Data is $-4.77.

The growth estimate for Weatherford International plc (NYSE:WFT) for the current quarter is 3.4 percent. The projected growth estimate for the next quarter is 14.3 percent. The company’s stock has grown by 14.45 percent in the past 5 years. For the next 5 years, the company is expected to grow by -23.56 percent.

This company was Upgrade by Loop Capital on 3-Feb-17  to Buy.

The 34 analysts offering 12-month price forecasts for Weatherford International PLC have a median target of 7.00, with a high estimate of 12.00 and a low estimate of 3.00. The median estimate represents a 16.67% increase from the last price of 6.00.

Financial History:

Following Earnings result, share price were UP 19 times out of last 31 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 58% percent of times. It has met expectations  1 times and missed earnings  4  times.

The consensus recommendation for Weatherford International plc (NYSE:WFT) is 2.05. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The consensus recommendation 30 days ago for this company stood at 1.95. In comparison, the consensus recommendation 60 days ago was at 1.95, and 90 days ago was at 2.09 respectively.

Future Expectations:

When the current quarter ends, Wall Street expects Weatherford International plc to have earnings per share of $-0.28.

Revenue is expected to range from 1.33 Billion to 1.52 Billion with an average of 1.38 Billion.

Company Profile:

Weatherford International is one of the world’s leading providers of equipment and services used for the drilling, completion and production of oil and natural gas wells. Its operations are conducted in numerous countries and it has service and sales locations in substantially all of the oil and natural gas producing regions in the world. The company’s products and services are divided into the following four principal operating divisions: Drilling and Intervention Services; Completion Systems; Artificial Lift Systems; and Compression Services.

Galena Biopharma, Inc. (NASDAQ:GALE):

Galena Biopharma, Inc. (NASDAQ:GALE) belongs to Medical sector closed its last session with a gain of 17.5 percent and closed its previous trading session at $1.41. According to Finviz reported data, the stock currently has Earnings per Share (EPS) (ttm) of $-2.32. The company has the Market capitalization of $14.34 Million. The company’s stock has a Return on Assets (ROA) of -51.1 percent, a Return on Equity (ROE) of -214.9 percent and Return on Investment (ROI) of 0 percent. The company reached its 52-Week high of $4.75 on Nov 21, 2016 and 52-Week low of $0.16 on Nov 9, 2016.

This company was Downgrade by FBR & Co. on 6-Feb-17 to Mkt Perform.

There is no forecast data available.

Financial History:

Following Earnings result, share price were DOWN 16 times out of last 28 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 50% percent of times. It has met expectations  2  times and missed earnings  4  times.

The consensus recommendation for Galena Biopharma, Inc. (NASDAQ:GALE) is 2.5. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The consensus recommendation 30 days ago for this company stood at 2. In comparison, the consensus recommendation 60 days ago was at 2, and 90 days ago was at 2 respectively.

Future Expectations:

When the current quarter ends, Wall Street expects Galena Biopharma, Inc. to have earnings per share of $-0.77.

Company Profile:

Galena Biopharma, Inc. is a biopharmaceutical company that develops innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care. Galena Biopharma, Inc., formally known as RXi Pharmaceuticals Corporation, is based in Portland, Oregon.